MN HF81

Minnesota Board of Pharmacy must establish a pharmacogenomics (PGx) task force to evaluate statewide availability and develop recommendations for implementing PGx services, defined as determining how genomic variation affects medication safety and efficacy.

Task force membership includes at least 15 appointed positions (pharmacists, physicians, health system administrators, patient representatives, biotechnology and payer representatives, health informatics experts, genetic counselors, and others) plus four legislative members, with initial appointments due by September 1, 2021.

Task force duties include analyzing implementation strategies, identifying healthcare workforce education needs, soliciting public input on readiness for PGx adoption, and developing recommendations for service diffusion, provider education, health benefits evaluation, and research capacity building.

Executive director must report to legislative health committees by June 30, 2022 on task force goals and independent recommendations; task force expires September 1, 2022.

$250,000 is appropriated from the general fund to the Minnesota Board of Pharmacy in fiscal year 2022 as a one-time appropriation for the task force.